ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years
Gary L. Johnson
Matched on ORCID iD 0000-0003-2867-0551; OpenAlex author ID A5047612906; NIH RePORTER profile ID 1863349. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 3
- Labs led
- 0
- Collaborators
- 19
2018: 1 paper · 2019: 1 grant · 2020: 1 paper · 2021: 1 grant · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 grant
Papers 4
- Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches. Co-author DOI 10.1158/2159-8290.cd-23-1480↗
- Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines. Co-author DOI 10.7717/peerj.17797↗
- Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. Co-author DOI 10.1172/jci.insight.129905↗
- Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth. Co-author DOI 10.1177/2472555218773045↗
Grants 3
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jen Jen Yeh · 4 shared papers, 3 shared grants, 2018–2026 · strength 2.60
- Lee M. Graves · 2 shared papers, 1 shared grant, 2018–2021 · strength 0.54
- Grant Tumor Subtypes and Therapy Response in Pancreatic Cancer R01CA199064↗
- Paper Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. DOI 10.1172/jci.insight.129905↗
- Paper Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Can… DOI 10.1177/2472555218773045↗
- Naim U. Rashid · 3 shared papers, 2020–2025 · strength 0.49
- Paper Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines. DOI 10.7717/peerj.17797↗
- Paper Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches. DOI 10.1158/2159-8290.cd-23-1480↗
- Paper Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. DOI 10.1172/jci.insight.129905↗
- Shawn M. Gomez · 2 shared papers, 2024–2025 · strength 0.39
- Susan Tsai · 1 shared grant, 2021 · strength 0.38
- Matthew B. Lipner · 2 shared papers, 2020–2024 · strength 0.30
- Matthew E. Berginski · 1 shared paper, 2024 · strength 0.20
- Alina Cornelia Iuga · 1 shared paper, 2025 · strength 0.19
- Michael Haas · 1 shared paper, 2025 · strength 0.19
- Steffen Ormanns · 1 shared paper, 2025 · strength 0.19
- Lisa Miller‐Phillips · 1 shared paper, 2025 · strength 0.19
- Yi Xu · 1 shared paper, 2025 · strength 0.19
- Volker Heinemann · 1 shared paper, 2025 · strength 0.19
- Stefan Hubert Boeck · 1 shared paper, 2025 · strength 0.19
- Yi Xu · 1 shared paper, 2020 · strength 0.09
- Richard A. Moffitt · 1 shared paper, 2020 · strength 0.09
- Cyrus Vaziri · 1 shared paper, 2020 · strength 0.09
- Linas J. Krulikas · 1 shared paper, 2018 · strength 0.07
- Antonio T. Baines · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.